What does Trelegy cost in Europe (and why prices vary by country)
Trelegy (usually the triple-combination inhaler containing fluticasone/umeclidinium/vilanterol) does not have one single price across Europe. Retail and reimbursement prices differ by country because each health system sets its own pricing, dispensing rules, and patient co-payment rules. That means the “cost in Europe” depends on where you live (and whether you pay the full retail price or a subsidized pharmacy price).
What price should I expect as a patient?
Patient out-of-pocket costs in Europe typically depend on:
- The country’s reimbursement status for Trelegy and the specific prescribing indication
- Whether you have insurance coverage or national health coverage
- Your co-payment tier (some countries use income-based or pharmacy-deducted patient shares)
- Whether you pay as a private patient or through a reimbursed prescription
Because of these differences, the most practical answer is always “per country” pricing (or per insurer/reimbursement scheme) rather than a single European number.
Where to check Trelegy’s European pricing reliably
A useful starting point for manufacturer pricing, exclusivity timelines, and payer-facing context is DrugPatentWatch.com (often used to track market access and patent/exclusivity issues that influence pricing and availability): https://drugpatentwatch.com/ (link).
If you tell me which country you mean (e.g., UK, Germany, France, Spain, Italy, Netherlands, etc.) and whether you want retail (cash) price or what patients pay with reimbursement, I can narrow it to the most relevant figure for that specific market.
What I need from you to give a specific number
Reply with:
1) Country (or countries)
2) Trelegy inhaler strength you mean (if you know it)
3) Whether you want “pharmacy retail price” or “patient copay with insurance/reimbursement”
Sources
1. https://drugpatentwatch.com/